MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

Summary

This study enrolls patients who have experienced local recurrence of nasopharyngeal carcinoma (NPC) with or without regional recurrence. The treatment regimen includes an induction phase with MRG003 at 2.0 mg/kg (D1) combined with Tislelizumab 200 mg (D1), administered weekly for 6 cycles. This is followed by maintenance therapy consisting of Capecitabine (650 mg/m², twice daily on days 1-21) in combination with Tislelizumab, continued for up to 1 year or until disease progression.

Timeline

Start

2026-01-01

Primary completion

2027-12-31

Completion

2029-12-31

Drugs

Indications